Neurocrine Biosciences (NBIX) Selling, General & Administrative (2010 - 2026)
Neurocrine Biosciences (NBIX) Selling, General & Administrative (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 317.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | -1.80 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 206.70 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 1.13 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 439.70 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 449.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 217.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 439.70 Mn |
| Mar 31, 2026 | 318.50 Mn |
| Dec 31, 2025 | 301.80 Mn |
| Sep 30, 2025 | 291.60 Mn |
| Jun 30, 2025 | 286.30 Mn |
| Mar 31, 2025 | 276.50 Mn |
| Dec 31, 2024 | 287.80 Mn |
| Sep 30, 2024 | 234.30 Mn |
| Jun 30, 2024 | 242.00 Mn |
| Mar 31, 2024 | 243.10 Mn |
| Dec 31, 2023 | 218.90 Mn |
| Sep 30, 2023 | 204.20 Mn |
| Jun 30, 2023 | 221.80 Mn |
| Mar 31, 2023 | 242.70 Mn |
| Dec 31, 2022 | 182.90 Mn |
| Sep 30, 2022 | 186.30 Mn |
| Jun 30, 2022 | 182.80 Mn |
| Mar 31, 2022 | 200.70 Mn |
| Dec 31, 2021 | 156.50 Mn |
| Sep 30, 2021 | 154.60 Mn |